MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
Status:
Completed
Trial end date:
2012-09-20
Target enrollment:
Participant gender:
Summary
This study has two parts. In the first part, the efficacy and safety MK-0954E (losartan
potassium 50 mg [L50] (+) hydrochlorothiazide 12.5 mg [H12.5] (+) amlodipine besylate 5mg
[A5]) will be evaluated and compared to the efficacy and safety of MK-0954H (L50/H12.5) in
Japanese participants. In the second part, the safety and tolerability of long-term use of
open-label MK-0954E in participants with hypertension will be evaluated. The primary
hypothesis is that MK-0954E is more effective in lowering mean trough sitting diastolic blood
pressure (SiDBP) after 8 weeks of treatment compared to MK-954H (L50/H12.5 mg) in Japanese
participants with essential hypertension who are not adequately controlled following a 8-week
treatment with filter period study drug of MK-954H.